Abstract:Objective To establish the synthesis and purification methods of BSA-(Gd-DTPA)n-CR and conduct its characterization and preliminary evaluation in vivo and in vitro, and to explore its ability to bind to amyloid plaques and application prospect as a high-performance relaxation magnetic resonance imaging agent precursor. Methods BSA-(Gd-DTPA)n-CR was prepared according to previously described protocols on the binding interaction of CR with BSA with several modification. Purification and identification of BSA-(Gd-DTPA)n-CR was performed by using a Sephadex LH20 gel column chromatography and UV spectroscopy. The relaxation rates r1/r2 of the complex were further analyzed by measuring the relaxation time T1/T2 of the complex in vitro. The drug safety was evaluated by acute toxicity test.The coronal T1W images of mouse hearts and livers at different times by a single tail vein injection with BSA-(Gd-DTPA)n-CR were obtained with the Flash 3D sequence.Its ability to bind to amyloid plaques was evaluated by brain sections from APP/PS1 transgenic mice. Its specificity for Aβ plaques was further demonstrated by immunohistochemistry (IHC) staining with the monoclonal antibody to the Aβ protein. Results A novel specific MRI probe precursor BSA-(Gd-DTPA)n-CR based on DTPA-gadolinium (III) and congo red (CR) was successfully synthesized. Meanwhile, the amyloid deposits detected by the BSA-(Gd-DTPA)n-CR were matched to the amyloid deposits detected by Aβ specific antibody. But a few amyloid-like deposits which was not detected by IHC. The findings indicated that the probe perhaps could detect the neurofibrillary tangles (NFT) similar to the effect of CR itself, and this will be verified in future experiments. Conclusions The study suggested that the Aβ protein-specific magnetic resonance contrast agent precursor BSA-(Gd-DTPA)n -CR can be used as a potential fluorescence and MR multi-modal imaging probe precursor to display individual senile plaques in AD.

Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease

Study of Specially Labeling Amyloid Plaques in Vivo in Alzheimer Transgenic Mice with Targeted Magnetic Nano-Iron Contrast Agent

[In Vitro Early Detection of Amyloid Plaques in Alzheimer's Disease by Pittsburgh Compound B-modified Magnetic Nanoparticles].

Evaluation of Dimercaptosuccinic Acid-Coated Iron Nanoparticles Immunotargeted to Amyloid Beta as MRI Contrast Agents for the Diagnosis of Alzheimer's Disease

Detection of Aβ Plaques by a Novel Specific MRI Probe Precursor CR‐BSA‐(Gd‐DTPA)n in APP/PS1 Transgenic Mice

Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease

Smart Near-Infrared Fluorescence Probes with Donor–Acceptor Structure for in Vivo Detection of Β-Amyloid Deposits

Early Detection of Amyloid Pathology in Alzheimer's Disease by Molecular MRI

A Novel Magnetic Nanoparticle for Early Detection of Amyloid Plaques in Alzheimer's Disease.

Preparation of Amyloid Immuno-Nanoparticles as Potential MRI Contrast Agents for Alzheimer's Disease Diagnosis.

[The Comparative Study on High Field MRI and Pathology of Alzheimer's Disease Transgenic Mice].

Noninvasive Visualization of Amyloid-Beta Deposits in Alzheimer's Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent

Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models

Development of A Novel Radioiodinated Compound for Amyloid and Tau Deposition Imaging in Alzheimer's Disease and Tauopathy Mouse Models

Imaging Brain Amyloid of Alzheimer Disease in Vivo in Transgenic Mice with an Aβ Peptide Radiopharmaceutical

Preparation, characterization and primary evaluation of Aβ protein targeting BSA-(Gd-DTPA)n–CR complex for magnetic resonance contrast enhancement in Alzheimer's disease

Evaluation of the biodistribution and preliminary safety profile of a novel brain-targeted manganese dioxide-based nanotheranostic system for Alzheimer's disease

Amyloid-β Deposits Target Efficient Near-Infrared Fluorescent Probes: Synthesis, in Vitro Evaluation and in Vivo Imaging.

Visualizing Aβ Deposits in Live Young AD Model Mice with a Simple Red/near-Infrared-fluorescent AIEgen

High-fidelity imaging of amyloid-beta deposits with an ultrasensitive fluorescent probe facilitates the early diagnosis and treatment of Alzheimer's Disease

Targeted Magnetic Nanoparticles for Beta-Amyloid Detection